PPCB · Propanc Biopharma, Inc.

Summary

Propanc Biopharma, Inc. (PPCB) is a development-stage biopharmaceutical company focused on developing PRP, a proenzyme therapy targeting pancreatic, ovarian, and colorectal cancers by eradicating cancer stem cells to prevent recurrence and metastasis. PRP is in preclinical development, with plans to initiate human clinical trials in 2026 pending funding. The company has 85 granted patents covering proenzymes against solid tumors and collaborations with universities like Jaén and Granada. This S-1/A registers 7,000,000 shares of common stock for resale by Selling Stockholder Hexstone Capital LLC, issuable upon conversion of 100 shares of Series C Preferred Stock (stated value $10,000 each) acquired in a November 4, 2025 private placement for $1,000,099, plus warrants for 9,900 more Series C shares. The company receives no proceeds from resales but bears registration costs. Financially, Propanc reports no revenue, a $58.9M net loss for FY 2025 (up from $1.8M in FY 2024), $12K cash, $134M accumulated deficit, and $55K outstanding convertible notes as of December 31, 2025. It relies on equity/debt financings amid going concern doubts. The filing enables liquidity for Hexstone while highlighting high risks from early-stage status, funding needs, clinical uncertainties, and dilution.

Key takeaways

• Registering 7,000,000 shares for resale by Hexstone Capital LLC upon conversion of 100 Series C Preferred shares from November 4, 2025 private placement yielding $1,000,099.
• PRP in preclinical stage; plans First-In-Human Phase Ib trials in 2026 for advanced solid tumors if funded.
• FY 2025 net loss $58.9M vs. $1.8M FY 2024; $12K cash, $134M accumulated deficit as of Dec 31, 2025.
• 85 granted patents on proenzymes; Orphan Drug Designation for pancreatic cancer from FDA in June 2017.
• No proceeds to company from resales; bears registration fees; Nasdaq-listed PPCB at $0.39/share on Jan 28, 2026.
• 15,091,133 common shares outstanding as of Jan 26, 2026; CEO Nathanielsz controls via Series B Preferred.
• Key risks: early-stage development failure, need substantial funding, clinical trial delays, dilution from convertibles.